DigniCap Delta Hair Loss Prevention System for Chemo Now in U.S.

Dignitana, a company out of Lund, Sweden, won FDA clearance and is now distributing its DigniCap Delta scalp cooling system in the U.S. The University of California, San Francisco (UCSF) will be the first recipient in America of the fourth generation...
Source: Medgadget - Category: Medical Devices Authors: Tags: Medicine Oncology Source Type: blogs

Related Links:

Authors: Xu J, Li D, Du K, Wang J Abstract Background: Cinobufacin is a Chinese patent medicine widely used for breast cancer in China. However, no systematic review and meta-analysis have been published to validate its effects in breast cancer treatment. We, therefore, summarize the efficacy and safety of Cinobufacin combined with chemotherapy in order to provide rigid evidence for its clinical application. Methods: By searching multiple databases incepted to December 2019, the RCTs of breast cancer patients treated with Cinobufacin were screened according to the inclusion criteria, and the meta-analysis and s...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
Background: The population-based Dutch Cancer Registry shows that 60% of patients with breast cancer received chemotherapy and 99% of these treatments are known to introduce severe alopecia. Worldwide scalp cooling is being implemented to prevent chemotherapy-induced alopecia (CIA). FDA clearance has been approved for scalp cooling among breast cancer patients in 2015. It is heading towards standard care as it is added to the NCCN guideline for breast cancer in 2019.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: POSTERS A: Supportive and Palliative Care Including End of Life Treatment Source Type: research
Background: Breast cancer is the most common cancer among women worldwide. Post-operative chemotherapy plays an essential role in preventing recurrence and metastasis in patients with breast cancer. Since breast cancer chemotherapy has markedly improved in efficacy and has become more widely used, it is being administered to increasing numbers of patients. However, many patients may decline treatment because they are anxious about adverse effects, in particular hair loss. Cyclophosphamide, anthracycline, and taxane agents commonly cause hair loss, nausea, vomiting, and fever.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: POSTERS A: Supportive and Palliative Care Including End of Life Treatment Source Type: research
CONCLUSIONS: Severe CIA occurred in all 68 patients who received FEC and taxane chemotherapy. The present findings provide the first data demonstrating that age was not associated with the degree or incidence of hair loss, but age affected the recovery from CIA. These results contribute more accurate information provision and insights regarding the proper treatment of CIA. PMID: 32944881 [PubMed - as supplied by publisher]
Source: Breast Cancer - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research
This genetic association study explores whether an association exists between genetic factors and the development of persistent chemotherapy-induced alopecia in women with breast cancer who are treated with docetaxel.
Source: JAMA Dermatology - Category: Dermatology Source Type: research
Conclusions: The quality of life in women with breast cancer and under chemotherapy was mainly affected by the side effects of the therapy; the most relevant signs and symptoms identified were hair loss, insomnia, and fatigue besides breast symptoms, lower physical functionality, and decreased sensation of sexual pleasure. We recommend intervention strategies aimed at improving the quality of life and the physical and emotional care of these patients. PMID: 32673462 [PubMed - in process]
Source: Biomedica : Revista del Instituto Nacional de Salud - Category: International Medicine & Public Health Tags: Biomedica Source Type: research
Purpose: Permanent chemotherapy-induced alopecia (pCIA) is an increasingly recognised complication of taxane-based chemotherapy that may be associated with significant psychological morbidity [1]. The prevalence of pCIA following docetaxel is poorly understood and there are no published data on paclitaxel chemotherapy. Here we analyse prevalence and patterns of pCIA in patients who received docetaxel or paclitaxel across two UK tertiary cancer centres.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
             Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Phesgo ™, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC i...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
ConclusionsSleep disturbances have lately emerged as the most severe problem in women with OC or BC receiving anticancer therapy. Concerns about family and partner were ranked second in the current study and first in previous investigations.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
ConclusionsThis study indicates that carboplatin plus taxanes could be a feasible adjuvant chemotherapy for patients with early TNBC who are cannot tolerate intensive chemotherapy with anthracycline.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Alopecia | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Medical Devices | Nurses | Nursing | Sweden Health